Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 961,364	$ 526,423
Accounts receivable	233
Prepaid expenses and other current assets	20,216	11,406
Research and development incentives receivable	46,443	24,039
Total current assets	1,028,256	561,868
Property and equipment, net	11,587	14,515
Operating lease right-of-use assets	10,933	13,169
Other assets	6,579	5,792
Total assets	1,057,355	595,344
Current liabilities:
Accounts payable	7,453	13,050
Accrued expenses and other current liabilities	28,135	31,509
Deferred revenue, current portion	11,619	24,978
Debt, current portion	22,404
Total current liabilities	69,611	69,537
Debt, net of discount and current portion	8,505	30,698
Operating lease liabilities, net of current portion	6,730	9,382
Deferred revenue, net of current portion	93,994	110,216
Other long-term liabilities	4,702	4,579
Total liabilities	183,542	224,412
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 154,385,145 and 59,612,613 shares authorized on June 30, 2024 and December 31, 2023, respectively; 68,941,242 and 42,431,766 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	889	550
Additional paid-in capital	1,452,151	883,446
Accumulated other comprehensive loss	(1,092)	(1,304)
Accumulated deficit	(578,135)	(511,760)
Total shareholders' equity	873,813	370,932
Total liabilities and shareholders' equity	$ 1,057,355	$ 595,344